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Background: To compare the efﬁcacy of in situ replacement with rifampicin-soaked silver-coated poly-
ester (RSSCP) to that of expanded polytetraﬂuoroethylene (ePTFE) graft replacements in a porcine model
for early aortic prosthetic vascular graft infection (PVGI).
Material and methods: Sixty pigs received polyester or silver-coated grafts with an 8 mm diameter
implanted end-to-end in the infrarenal aorta, and the grafts were inoculated with approximately 106
Staphylococcus aureus. All developed S. aureus PVGI. Two weeks later, the 52 surviving pigs were rand-
omised to undergo in situ graft replacement with ePTFE or RSSCP grafts followed by oral administration
of 300 mg rifampicin and 750 mg ciproﬂoxacin twice a day, postoperatively. After three weeks, all pigs
were sacriﬁced. In situ perigraft swabs and graft material were analysed for S. aureus quantitatively.
Results: Only one out of 25 RSSCP grafts were infected with S. aureus, whereas 15 of 27 ePTFE grafts were
infected after 3 weeks (OR ¼ 0.022, 95% CI: 0.002, 0.219, P ¼ 0.001).
Conclusions: In situ replacement with RSSCP grafts and oral rifampicin plus ciproﬂoxacin is more efﬁ-
ciency in eradicating S. aureus PVGI than ePTFE grafts treated with same oral antibiotics in a porcine
aortic PVGI model.
 2012 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.The treatment of a prosthetic vascular graft infection (PVGI) is
a challenge, and in spite of the improvement in sterile operative
conditions, surgical techniques, and the use of routine prophylactic
antibiotics, the overall prevalence ranges from 0.5% to 6%.1e3 The
most common bacteria in early PVGI (4 months) is Staphylococcus
aureus, accounting for 25e50% of isolates.2,4 When a PVGI occurs,
bacteriology-guided antibiotic administration, local debridement
of surrounding infected tissue, total graft removal and vascular
reconstruction are usually performed.
The application of the in situ replacement with an autogenous
conduit or allograft was performed due to a low reinfection rate and
high patency.3 However, if lacking suitable autogenous vessels and
allografts, the prosthetic graft may be the exclusive alternative.
Polyester and polytetraﬂuoroethylene are themost commonly used
prosthetic graft materials. Because of their surface properties and
structure, polyester grafts may be 10e100 times more likely to
become infected and to sustain the infection compared to PTFE.2,5þ45 7844 5659.
ciety for Vascular Surgery. PublishSome studies have demonstrated that the binding of antibiotic or
antiseptic compounds to polyester grafts, such as rifampicin-coated
or silver-coated grafts, could be more preventive against vascular
graft infection.6,7 However, some experimental and clinical trials
have presented results that indicated failure.8e11 The inability to
inhibit PVGI using only silver-coated or rifampicin-binding grafts
could be due by recurrent infection by non-eradicated bacteria.9
The aim of this study was to compare the efﬁcacy of in situ
replacement with rifampicin-soaked silver-coated polyester
(RSSCP) to that of expanded polytetraﬂuoroethylene (ePTFE) grafts
in a porcine model with early aortic methicillin susceptible
S. aureus PVGI.Material and Methods
We hypothesised that after in situ replacement for an infected
graft, RSSCP grafts aremore efﬁcacious in eliminating S. aureus than
the PTFE counterparts. The primary endpoint of this study was
persistent S. aureus (non-eradication) on the graft and the
surrounding tissue 3 weeks postoperatively.ed by Elsevier Ltd. All rights reserved.
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autopsy after in situ replacement was 50%. By randomising the type
of graft using a 5% signiﬁcance level and 80% power, a clinically
signiﬁcant 33% difference in the proportion of non-eradicated
grafts was identiﬁed.
Graft material
As an extension of a previous study, collagen-impregnated
polyester grafts with and without silver coating (INTERGARD
Knitted and Silver grafts, Intervascular, France) were used in
a porcine model for PVGI.11 After 14 days, RSSCP and ePTFE grafts
(GORE-TEX Stretch, W.L. Gore & Associates, United States) were
used for reimplantation. RSSCP grafts were composed of silver-
coated polyester immersed for 15 min in 30 ml normal saline
with 1800 mg rifampicin at room temperature before replacement.
All grafts were 8 mm in diameter.
Bacterial strain
The S. aureus strain ATCC 29213 used in this experiment also has
been used in several PVGI studies.12,13 The strain is susceptible to
oxacillin, gentamicin, ciproﬂoxacin, rifampicin, vancomycin and
cefoxitin but resistant to penicillin. The MIC of rifampicin, per-
formed by E-test, was less than 0.016 mg l1, and that of cipro-
ﬂoxacin was 0.25 mg l1.
The porcine model
The ﬁrst 60 of 84 2-month-old female pigs with PVGI, which
developed during our previous study,11 were included based on
power calculations To acclimate the pigs to an unfamiliar envi-
ronment, they were individually caged in the laboratory facilities
for 3 weeks prior to the surgery. Preoperatively, pigs with a mean
weight of 73  2.53 kg were randomised to have a segment of the
infrarenal aorta exchanged with a polyester graft or silver-coated
graft locally inoculated with approximately 106 S. aureus.11 On the
14th postoperative day, the reoperation was performed, including
the perigraft swabbing and the total graft removal for bacterial
analysis and debridement. The pigs were then randomised to
receive in situ replacement with an RSSCP or an ePTFE graft strat-
iﬁed for the initial types of grafts used. Consequently, an equal
distribution of RSSCP and ePTFE grafts among those receiving
a polyester graft or silver-coated graft, respectively, was secured. All
operative procedures were performed under standardised aseptic
conditions, and before retroperitoneal closure, the rifampicin
solution used to prepared the RSSCP grafts were left in the
debridement area to enhance the topical antibiotic treatment. Oral
administrations of 300 mg rifampicin and 750 mg ciproﬂoxacin
were given twice daily to all pigs for 21 days after reoperation.
Blood samples were taken to measure C-reactive protein (CRP) on
days 14, 21, 28 and 35. The concentrations of both antibiotics in the
serum were measured before in situ replacement, and on day 35,
which was 16 h after the last dose was provided.
Surgical procedure
The pigs were anaesthetised with a mixture consisting of zol-
amine (5 mg ml1), butorphanol (1 mg ml1), ketamine
(10 mg ml1) and xylazin (2 mg ml1), dosing 1 ml mixture per
15 kg bodyweight. Anaesthesia was maintained by an intravenous
infusion of propofol (10 mg ml1per hour) and fentanyl (l
0.025 mg ml1per hour). The pigs were ventilated with air
throughout the operation. All pigs received 1.5 g cefuroxime
intravenously just before the abdominal incision. The abdominalaorta was exposed from the crossing left renal vein to the aortic
bifurcation. The lumbar and inferior mesenteric arteries were
clipped and dissected. After intravenous administration of
a 5000 IU bolus of heparin, the infrarenal aorta was replaced with
an 8-mm-diameter polyester or silver-coated graft approximately
5 cm in length. The end-to-end anastomosis was performedwith 4/
0 polypropylene sutures. After haemostasis, the surfaces of the graft
were directly inoculated with approximately 106 S. aureus in a 0.3-
ml suspension using a 1-ml syringe. Hereafter, the retroperitoneum
and incision were closed in layers using standard surgical
techniques.11
After 2 weeks, the implanted grafts were exposed through the
previous incision under aseptic conditions. Signs of a graft infec-
tion, such as the status of perigraft tissue, exudation, pus, necrosis,
cavity formation, enteric erosion and anastomoses, were recorded.
After the perigraft swab sampling for bacterial examinations and
the debridement of perigraft pus and necrosis, the grafts were
totally excised along with the segments of the aorta within 5 mm of
the anastomoses. The perigraft area was washed with 300 ml 0.9%
saline solution. After randomisation, either an RSSCP or an ePTFE
graft was implanted by end-to-end anastomoses with 4/0 poly-
propylene sutures. Ten millilitres of rifampicin solution
(60 mg ml1) was poured onto the perigraft area of implantation
with the RSSCP graft prior to closure of the retroperitoneum, and
then the incision was closed with the standard surgical technique.
Anaesthesia, cefuroxime prophylaxis and dosing of heparin were
provided as in the primary operation.
All pigs received intramuscular injections of 150 mg ﬂunixin
once daily and 0.6 mg buprenorphine three times on days 1e3 after
the primary operation and reoperation for pain release. Post-
operatively, the pigs weremonitored daily, including registration of
food and water intake, weight, behaviour and measurement of
rectal temperatures with an electrical thermometer.
Twenty-one days after the reoperation, all surviving pigs
underwent euthanasia, and autopsies were performed. The pres-
ence of perigraft tissue changes, ﬂuid, pus and graft incorporation
was recorded. Perigraft swabs were taken, and whole grafts were
removed under sterile conditions for bacterial analysis.Bacterial examination
Perigraft swabs from reoperations and autopsies were placed
into the Stuart transport medium, and samplings of whole graft
from autopsies were placed in a separate sterile plastic tube for the
bacterial identiﬁcation and quantitative analysis.
The swabswere placed in 1ml saline and the cut pieces of whole
graft (less than 3  3 mm2) in 5 ml saline, and both were vortexed
for 2 min. Fifty microlitres of the suspension were diluted serially,
from 102 to 106, and incubated aerobically at 35 C overnight. The
ﬁnal quantitative results of bacteria in the swabs and on the grafts
were expressed as the number of colony forming units (CFUs).
Blood taken before the reoperation and on the day of autopsy
was analysed for concentration of antibiotics by bioassay.14 A
rifampicin-resistant but ciproﬂoxacin-susceptible Escherichia coli
and a ciproﬂoxacin-resistant but rifampicin-susceptible S. aureus
were used to estimate the antibiotic concentrations of ciproﬂoxacin
and rifampicin, respectively. Standard antibiotic concentrations
were diluted in a serum broth.Statistical analysis
P values less than 0.05 were considered to be statistically
signiﬁcant. SPSS version 15.0 was used as the statistical software
(SPSS Inc., Chicago, IL, USA).
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Inspection under the Danish Ministry of Justice.Results
Fifty-two pigs (87%) survived the reoperation and the admin-
istered 3-week antibiotic course. Before the reimplantation, four
pigs were euthanised due to graft thrombosis, spinal cord
ischaemia, peritonitis or S. aureus septicaemia (Fig. 1). After in situ
replacement, one pig died from acute thrombosis of the prosthetic
graft on day 1, and threewere euthanised on postoperative days 6, 7
and 12, due to graft thrombosis, spinal cord ischaemia or hind limb
pain, respectively (Fig. 1). Although eight pigs were lost due to
postoperative complications, the post hoc power calculation
demonstrated 99.4% power in the performed trial.
All primary grafts were infected with S. aureus after the inocu-
lation. During in situ replacement, macroscopic signs of theRSSCP: rifampicin-soaked silver-coated poly
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Figure 1. Flow chart ofinfection and positive S. aureus ﬁndings were similar in the RSSCP
and ePTFE graft groups (Table 1).
No macroscopic signs of the infection were observed at the ﬁnal
autopsies except in three RSSCP grafts and in two ePTFE grafts,
which all were infectedwith E. coli. Only 1 of 25 pigs (4%) implanted
with the RSSCP grafts harboured S. aureus (Table 1). However,
S. aureus was found in samples harvested from 15 of the 27 pigs
(56%) in the groupwith ePTFE grafts. After 3 weeks of treatment, no
strain of S. aureus developed resistance to rifampicin or cipro-
ﬂoxacin, which was detected with antibiotic susceptibility test. The
crude odds ratio for S. aureus infected RSSC grafts was 0.033 (95%
CI: 0.004, 0.283; logistic regression: P ¼ 0.002) compared to ePTFE,
and the adjusted odds ratio was 0.022 (95%CI: 0.002, 0.219; logistic
regression: P ¼ 0.001) after adjustment for the graft type, diet,
weight, number of perigraft S. aureus before reoperation and
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Table 1
Objective and cultural ﬁndings after two weeks of S. aureus infections in the aortic grafts and the ﬁndings observed 3 weeks after in situ replacement with rifampicin-soaked
silver grafts and ePTFE grafts treated with oral rifampicin and ciproﬂoxacin.
Infection
ﬁnding
Graft groups
At in situ replacement (2 weeks after inoculation
of 106 S. aureus)
At autopsy (further 3 weeks after in situ replacement a
nd antibiotic treatment)
RSSCP (n ¼ 25) ePTFE (n ¼ 27) RSSCP (n ¼ 25) ePTFE (n ¼ 27)
Macroscopic
signs
Perigraft pus 19d 15d 0 0
Perigraft exudates 25 26 1a 0
Necrosis 25 27 2a 0
Graft incorporation 0 0 25 27
Intra mural thrombus 25 27 3a,e 2a,e
Bacteriological
ﬁnding
S. aureus present No. of pig 25 27 1g 15g
Bacterial count (5.55  0.9)b,f (5.36  0.78)b,f 0.90c (2.93  1.45)c
Other bacteria than S. aureus 0 0 3a 2a
Total prosthetic vascular graft
infection
25 27 4h 16h
a Samples grew Escherichia coli.
b log10 (bacterial account) in perigraft swabs taken before replacement are expressed in mean  SD.
c log10 (bacterial account) in graft material are expressed in mean  SD.
d Fisher’s Exact Test, P ¼ 0.512.
e Fisher’s Exact Test, P ¼ 0.662.
f Student’s t-test, P ¼ 0.586.
g Fisher’s Exact Test, P < 0.001.
h Fisher’s Exact Test, P ¼ 0.003.
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with RSSCP grafts and 2 of 27 pigs with ePTFE grafts. Consequently,
the proportions of the non-sterile grafts at autopsy were 4/25 (16%)
and 16/27 (59%), respectively (OR: 0.13; 95% CI: 0.03, 0.56;
P ¼ 0.003). The source of E. coli is unknown, but the infections may
have resulted from contamination during the reimplantation or the
autopsy.
The mean of the CRP and rectal temperatures of each pig group
decreased continuously after reoperation (Fig. 2). The changes over
time of the CRP and the rectal temperature, however, were similar
between the two groups (Repeated measures ANOVA: P ¼ 0.985;
P ¼ 0.743; respectively).
Following the reoperation and 16 h after medications were
given, the median rifampicin concentration in serum was
0.032 mg l1 (range: 0.004e0.072 mg l1), and that of ciproﬂoxacin
was 0.125 mg l1 (range: 0.015e0.47 mg l1). There were no
statistically signiﬁcant differences in the concentrations of rifam-
picin (ManneWhitney U test: P ¼ 0.415) and ciproﬂoxacin
(ManneWhitney U test: P ¼ 0.397) between the two groups.
Discussion
Non-eradicated S. aureus remained in 4% of RSSCP grafts
compared with 56% of ePTFE grafts. Therefore, our experiment
clearly demonstrates that after in situ replacement of an infected
graft, the RSSCP grafts are more efﬁcient than ePTFE grafts in
limiting S. aureus infection.
Antibiotic coated grafts release an antibacterial substance to
avoid the possible contamination from the skin and the air at the
time of the graft implantation. Several antibiotics have been used in
earlier experimental studies.12,15,16 Rifampicin is the compound
most often selected.6,10,16,17 This antibiotic has a broad spectrum of
activity against Gram-positive bacteria, especially S. aureus.
Furthermore, the ability of rifampicin to bind collagen- or gelatine-
coated grafts prolongs the activity of the medication for at least 7
days.17 The soaking concentration of rifampicin (60 mg ml1) has
been used in most recent experimental tests and in the clinic.8,18e20
The rifampicin concentration is the most important determinant
for the anti-staphylococcal bioactivity, and the optimal efﬁcacy is
produced by soaking polyester grafts in a 60 mg ml1 rifampicinsolution for 15 min21 The same method has been used in several
experimental studies and in the clinic.6,16,20
The antibacterial activity of vascular grafts could be augmented
by prebinding of grafts with a combination of silver and an anti-
biotic. It has been demonstrated in a previous study that grafts
coated with a combination of silver and ciproﬂoxacin had statisti-
cally signiﬁcant higher antibacterial bioactivity compared to grafts
bound by antibiotics alone. This study also demonstrated that the
silver-coated grafts could retain a higher antibiotic concentration
following the implantation, indicating a prolonged release of anti-
biotic and silver at the perigraft site.22
As a result of possessing highly hydrophobic surfaces and being
relative nonporous, the ePTFE grafts have been generally accepted
as effective in avoiding bacterial adhesion. This was based on the
study of Schmitt,23 in which PTFE grafts presented lower quanti-
tative bacterial adhesion as compared to polyester grafts. The
results of previous studies also showed that Staphylococcus epi-
dermidis and S. aureus had higher afﬁnity to polyester grafts than to
ePTFE grafts24 and further demonstrated that ePTFE grafts main-
tained similar antibacterial as antibiotic-bound grafts. However,
our study showed that ePTFE grafts were prone to infection, while
only a few RSSCP grafts were infected. In theory, this will increase
the risk of recurrent macroscopic and clinically relevant PVGI. Our
goal of this study was not to demonstrate superiority of the RSSCP
graft but to clarify the most appropriate option. Consequently, our
institution has changed clinical practice from using the ePTFE graft
to using the RSSCP counterpart.
Several studies have shown that the use of antibiotic-bound
grafts or systemic antibiotic treatment alone cannot prevent
PVGI.9,19,25 Furthermore, the systemic administration of rifampicin
and ciproﬂoxacin in combination can avert the development of
rifampicin resistance and achieve a higher cure rate.26,27 In the
present study, the bacteria spread into the perigraft and the aortic
tissues 14 days after inoculation, and the infected tissues were not
completely cleared even after performing intensive debridement.
After in situ replacement, the rifampicin solution was left in the
RSSCP group to enhance the local antibiotic treatment. This method
may have led to the increased cure rate in the RSSCP group.
Therefore, the data support our proposal that a radical cure of PVGI
can only be achieved with a combination of a suitable surgical
Figure 2. Changes over time in mean rectal temperature and CRP in the 3 weeks
following situ replacement with rifampicin-soaked silver grafts and ePTFE grafts in
pigs treated with oral rifampicin and ciproﬂoxacin.
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regimen. Although the CRP and temperature changes over time and
the macroscopic signs of PVGI were the same between the RSSCP
and ePTFE graft groups, the susceptible S. aureuswere still detected
in the cases of both graft groups after the 3-week antibiotic treat-
ment. These results indicated that dormant PVGI may occur
because insufﬁcient antibiotics could not achieve a microbiological
cure. Based on the current clinical practice, antibiotics are often
given for more than 3 months when PVGI is diagnosed.2 Therefore,
if the duration of antibiotic treatment had been prolonged in the
present study, the rate of eradication of S. aureus may have been
improved in both groups.
However, our consulted microbiologists believe that a 3-week
period is sufﬁcient to eradicate S. aureus. If a less virulent bacteria,such as S. epidermidis, had been chosen, a longer course would have
been necessary.
In this study, the vortex agitationmethodwas applied to harvest
bacteria from the grafts. However, using an ultrasonic bath treat-
ment might have increased the bacteria ﬁndings of both grafts, and
this method will be considered in our future study.
In conclusion, in situ replacements in a porcine PVGI model of
the RSSCP grafts followed by an oral treatment with rifampicin and
ciproﬂoxacin were more effective in eradicating S. aureus than
ePTFE graft replacements followed by the same antibiotic regimen.
The comparison between the non-silver, rifampicin-coated poly-
ester and RSSCP grafts could be an interesting topic for future
investigation.
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